Matches in SemOpenAlex for { <https://semopenalex.org/work/W2908708328> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2908708328 abstract "Background Rheumatoid arthritis (RA) is a chronic inflammatory bone-destructive disorder with autoimmune features. Apremilast is a novel phosphodiesterases 4 (PDE4) inhibitor suppressing immune and inflammatory responses. Objectives We assessed the anti-inflammatory and bone protection effects of apremilast in collagen CII induced arthritis (CIA)models. Methods Apremilast was given starting from day 14 after immunisation, we investigated whether apremilast (5 mg/kg or 25 mg/kg) can ameliorate arthritis onset. Bone erosion was measured by histological and micro-computed tomographic analysis. Anti–mouse type II collagen (CII) antibody levels were measured by enzyme-linked immunosorbent assay. Human cartilage and rheumatoid arthritis (RA) synovial fibroblasts (RASFs) implantation in the severe combined immunodeficiency (SCID) mouse model of RA were used to study the role of apremilast in suppression of RASFs destroying cartilage in vivo. Results We found that apremilast therapy delayed arthritis onset and reduced arthritis scores in CIA model at a different dose, compared to CIA model and blank vector (figure 1A). Total serum IgG, IgG1, IgG2a, and IgG2b were all decreased in apremilast groups. Furthermore, apremilast can prevent CIA mice from bone erosion by CT analysis. High dose of apremilast (25 mg/kg) was superior to low dose (5 mg/kg) in treating CIA (figure 1B, C). Apremilast treatment can inhibit destroy and migratory ability of RASFs to cartilages. Compared to the model group, Apremilast treatment significantly reduced the invasion scores in both primary implant and contralateral implant. Conclusions Our data suggest that apremilast was effective in preventing arthritis and bone erosion in CIA model, implicating a potential promise of therapy on rheumatoid arthritis. Acknowledgements This work is supported in part by the grants from the Celgene Foundation, NIH R01 059103, National Natural Science Foundation of China (81671611, 81701600). Disclosure of Interest None declared" @default.
- W2908708328 created "2019-01-25" @default.
- W2908708328 creator A5010557193 @default.
- W2908708328 creator A5017717398 @default.
- W2908708328 creator A5035534167 @default.
- W2908708328 creator A5037023113 @default.
- W2908708328 creator A5053657605 @default.
- W2908708328 creator A5070670767 @default.
- W2908708328 creator A5090612941 @default.
- W2908708328 date "2018-06-01" @default.
- W2908708328 modified "2023-09-27" @default.
- W2908708328 title "THU0097 Phosphodiesterases 4 (PDE4) inhibitor ameliorates experimental arthritis" @default.
- W2908708328 doi "https://doi.org/10.1136/annrheumdis-2018-eular.4989" @default.
- W2908708328 hasPublicationYear "2018" @default.
- W2908708328 type Work @default.
- W2908708328 sameAs 2908708328 @default.
- W2908708328 citedByCount "0" @default.
- W2908708328 crossrefType "proceedings-article" @default.
- W2908708328 hasAuthorship W2908708328A5010557193 @default.
- W2908708328 hasAuthorship W2908708328A5017717398 @default.
- W2908708328 hasAuthorship W2908708328A5035534167 @default.
- W2908708328 hasAuthorship W2908708328A5037023113 @default.
- W2908708328 hasAuthorship W2908708328A5053657605 @default.
- W2908708328 hasAuthorship W2908708328A5070670767 @default.
- W2908708328 hasAuthorship W2908708328A5090612941 @default.
- W2908708328 hasBestOaLocation W29087083281 @default.
- W2908708328 hasConcept C105702510 @default.
- W2908708328 hasConcept C126322002 @default.
- W2908708328 hasConcept C203014093 @default.
- W2908708328 hasConcept C2776260265 @default.
- W2908708328 hasConcept C2776821229 @default.
- W2908708328 hasConcept C2777077863 @default.
- W2908708328 hasConcept C2777575956 @default.
- W2908708328 hasConcept C2780550940 @default.
- W2908708328 hasConcept C2781427535 @default.
- W2908708328 hasConcept C71924100 @default.
- W2908708328 hasConceptScore W2908708328C105702510 @default.
- W2908708328 hasConceptScore W2908708328C126322002 @default.
- W2908708328 hasConceptScore W2908708328C203014093 @default.
- W2908708328 hasConceptScore W2908708328C2776260265 @default.
- W2908708328 hasConceptScore W2908708328C2776821229 @default.
- W2908708328 hasConceptScore W2908708328C2777077863 @default.
- W2908708328 hasConceptScore W2908708328C2777575956 @default.
- W2908708328 hasConceptScore W2908708328C2780550940 @default.
- W2908708328 hasConceptScore W2908708328C2781427535 @default.
- W2908708328 hasConceptScore W2908708328C71924100 @default.
- W2908708328 hasLocation W29087083281 @default.
- W2908708328 hasOpenAccess W2908708328 @default.
- W2908708328 hasPrimaryLocation W29087083281 @default.
- W2908708328 hasRelatedWork W1973651315 @default.
- W2908708328 hasRelatedWork W1983480010 @default.
- W2908708328 hasRelatedWork W1986099984 @default.
- W2908708328 hasRelatedWork W2010682584 @default.
- W2908708328 hasRelatedWork W2011325735 @default.
- W2908708328 hasRelatedWork W2014785961 @default.
- W2908708328 hasRelatedWork W2043112612 @default.
- W2908708328 hasRelatedWork W2066614216 @default.
- W2908708328 hasRelatedWork W2317085820 @default.
- W2908708328 hasRelatedWork W2321799443 @default.
- W2908708328 hasRelatedWork W2333341546 @default.
- W2908708328 hasRelatedWork W2514398264 @default.
- W2908708328 hasRelatedWork W2807843185 @default.
- W2908708328 hasRelatedWork W2885010587 @default.
- W2908708328 hasRelatedWork W2937122378 @default.
- W2908708328 hasRelatedWork W2946846310 @default.
- W2908708328 hasRelatedWork W3046713541 @default.
- W2908708328 hasRelatedWork W3124092673 @default.
- W2908708328 hasRelatedWork W50342711 @default.
- W2908708328 hasRelatedWork W3170011881 @default.
- W2908708328 isParatext "false" @default.
- W2908708328 isRetracted "false" @default.
- W2908708328 magId "2908708328" @default.
- W2908708328 workType "article" @default.